MedTrace Logo

Efficacy Study of CYT997 in Multiple Myeloma

NCT00664378 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-06-08

No results posted yet for this study

Summary

This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.

Conditions

  • Relapsed and Refractory Multiple Myeloma

Interventions

DRUG

CYT997

Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle

Sponsors & Collaborators

Principal Investigators

  • Andrew Spencer, Assoc Prof. · Myeloma Research Group, The Alfred Hospital, Melbourne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664378 on ClinicalTrials.gov